JOHN FREDERICK DE GROOT to Protein Kinase Inhibitors
This is a "connection" page, showing publications JOHN FREDERICK DE GROOT has written about Protein Kinase Inhibitors.
Connection Strength
0.459
-
Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Neuro Oncol. 2016 09; 18(9):1230-41.
Score: 0.176
-
Improving the prognosis for patients with glioblastoma: the rationale for targeting Src. J Neurooncol. 2009 Nov; 95(2):151-163.
Score: 0.109
-
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro Oncol. 2018 09 03; 20(10):1411-1418.
Score: 0.052
-
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):249-258.
Score: 0.050
-
Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. Invest New Drugs. 2015 Feb; 33(1):247-53.
Score: 0.040
-
Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther. 2007 Apr; 6(4):1357-67.
Score: 0.024
-
Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. Cancer Lett. 2010 Dec 08; 298(2):139-49.
Score: 0.008